SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
January 27, 2015
KONINKLIJKE PHILIPS N.V.
(Exact name of registrant as specified in its charter)
Royal Philips
(Translation of registrants name into English)
The Netherlands
(Jurisdiction of incorporation or organization)
Breitner Center, Amstelplein 2, 1096 BC Amsterdam, The Netherlands
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(1): ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule101(b)(7): ¨
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
Name and address of person authorized to receive notices
and communications from the Securities and Exchange Commission:
M.J. van Ginneken
Koninklijke Philips N.V.
Amstelplein 2
1096 BC Amsterdam The Netherlands
This report comprises a copy of the following press release:
| Philips Fourth Quarter and Annual Results 2014, dated January 27, 2015. |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf, by the undersigned, thereunto duly authorized at Amsterdam, on the 27th of January, 2015.
KONINKLIJKE PHILIPS N.V.
/s/ M.J. van Ginneken
(General Secretary)
Q4 2014 Quarterly report
Philips reports Q4 sales of EUR 6.5 billion and operational results of EUR 743 million
Group Financials have been restated as of the fourth quarter of 2014 and for prior periods to show the results of the combined businesses of Lumileds and Automotive as discontinued operations in connection with the process of attracting third-party investors.
Fourth-quarter highlights
| Comparable sales declined 2% |
| EBITA, excluding restructuring and acquisition-related charges and other items, amounted to EUR 743 million, or 11.4% of sales, compared to 12.9% in Q4 2013 |
| EBITA amounted to EUR 262 million, impacted by restructuring costs and other items, compared to EUR 789 million in Q4 2013 |
| Net income amounted to EUR 134 million, compared to EUR 412 million in Q4 2013 |
| Free cash flow improved to EUR 559 million, compared to EUR 481 million in Q4 2013 |
Full-year highlights
| Comparable sales declined 1% to EUR 21.4 billion |
| EBITA, excluding restructuring and acquisition-related charges and other items, amounted to EUR 1.9 billion, or 9.0% of sales, compared to EUR 2.3 billion, or 10.5% of sales, in 2013 |
| EBITA amounted to EUR 821 million, or 3.8% of sales, compared to EUR 2.3 billion, or 10.4% of sales, in 2013 |
| Net income amounted to EUR 411 million, compared to EUR 1.2 billion in 2013 |
| Free cash flow improved to EUR 497 million, compared to EUR 82 million in 2013 |
| Return on invested capital was 4.5%, compared to 13.9% in 2013 |
| Proposal to maintain dividend at EUR 0.80 per share |
Frans van Houten, CEO:
The fourth quarter underscored a challenging 2014 for Philips. Our transformation efforts continued to show good results, even as we addressed performance issues, ongoing softness in end-markets like China and Russia, and stronger than anticipated foreign exchange impacts, particularly in emerging markets.
Healthcare was down overall, mainly caused by operational issues and soft markets. We were encouraged by market share gains in image-guided therapy and recorded strong orders in Europe and the Middle East, where we signed four multi-year solution deals. Our Cleveland factory resumed shipments to customers in January, marking an important milestone. Consumer Lifestyle performed very well in the quarter, continuing its three-year market-outperformance trend. Our Health & Wellness business delivered double-digit growth and we saw overall strong growth in EBITA.
Lighting recorded 20% sales growth in LED and expanded its margins in LED despite strong price erosion. Performance was, however, negatively impacted by results in China, Professional Lighting Solutions North America and conventional lighting. We took action to further restructure our manufacturing footprint in conventional lighting.
Update on Financial Targets
Overall, 2014 was a setback in our performance trajectory. We have been taking clear actions to drive stronger operational performance across our businesses and expect sales growth and EBITA margin improvements in 2015 and beyond. However, looking ahead, we remain cautious regarding the macroeconomic outlook and expect ongoing volatility of some of our end-markets. We also anticipate further incidental costs in 2015 and 2016, mainly in relation to restructuring and the separation.
Due to these factors, we are tracking 1 percentage point behind on the path to achieving each of our 2016 comparable sales growth, EBITA and ROIC Group targets. We are convinced that this does not change our longer-term performance potential, considering the attractiveness of the Lighting Solutions and HealthTech markets and our competitive position. Later this year, as we progress with the separation of Philips and reallocation of IG&S, we will update the market about the integral performance targets for each of the two operating companies.
Accelerate! and Separation Update
Accelerate! continues to drive improvements across the organization, resulting in increased customer centricity, enhanced customer service levels, faster time-to-market for our innovations and better cost productivity.
In Healthcare Informatics, Solutions & Services (HISS ), a new Agile software development methodology was implemented that increases the number of new software releases by four times over the year, enabling us to introduce a record number of new clinical informatics solutions in the IntelliSpace family at the Radiology Society of North America (RSNA) trade show. In Consumer Lifestyle, our deep understanding of local shopper needs allowed us to successfully launch an optimized range of male grooming products in France, meeting key price points and customer needs. This locally relevant value proposition resulted in a 2 percentage-point market share gain since launch and a record number of Philips product listings at retailer Carrefour. In Lighting, Professional Lighting Solutions enhanced its product portfolio for the indirect channel in Europe, which drove more than 60% sales growth as a result of its strong price-performance ratio, locally relevant value proposition and delivery time commitment of 5 days.
Overhead cost savings amounted to EUR 35 million for the quarter, bringing the total overhead cost savings in 2014 to EUR 284 million. The Design for Excellence (DfX) program generated EUR 123 million of incremental savings in procurement in the fourth quarter, bringing total DfX savings for 2014 to EUR 284 million. The End2End productivity program achieved incremental savings of EUR 22 million in the quarter, which brings the total End2End productivity savings to EUR 79 million for full-year 2014. Philips expects restructuring costs in 2015 of approximately EUR 250 million.
In September of last year, Philips announced its plan to separate into two standalone companies, positioning each one to better capitalize on the highly attractive HealthTech and Lighting solutions opportunities. Philips is confident in its ability to deliver additional growth and create more value through enhanced focus and agility. As indicated previously, the separation process will take approximately 12-18 months and further updates will be provided over the course of the year. The company currently estimates separation costs to be in the range of EUR 300-400 million in 2015.
The company is in discussion with external investors for the combined Lumileds and Automotive lighting businesses and expects to complete a transaction in the first half of 2015.
As of December 31, 2014, Philips had completed 41% of the EUR 1.5 billion share buy-back program.
Q4 overview
Healthcare
Healthcare comparable sales were 3% lower. The EBITA margin, excluding restructuring and acquisition-related charges and other items, was 14.8%, down from 19.0% year-on-year. Currency-comparable equipment order intake showed a mid-single-digit decline, although it improved in Western Europe. The impact of Cleveland on sales and order intake was approximately 4 percentage points, which will also impact growth performance in 2015.
In Healthcare, our strategic focus on large-scale and multi-year partnerships continues to gain traction. Furthermore, our pending acquisition of Volcano, announced in December, will enable us to deepen customer relationships, gain share and accelerate revenue growth for Philips leading image-guided therapy business.
The updated quality management system at our Cleveland facility recently passed the third-party audit and we have now resumed shipments of our Brilliance iCT systems. Due to the slower than anticipated ramp-up of production and shipments, the impact on 2014 EBITA was larger than previously anticipated. Passing the third-party audit for the production of the Brilliance iCT systems is an important milestone that enables us to focus on building further momentum as we deliver imaging innovations to our customers. We are also ramping up the production of CT systems in our facilities in Haifa and Suzhou, initially for customers outside of the United States. Our remediation work will continue to weigh on 2015 and we expect our global CT system production and shipment volume to only gradually return to 2013 levels by the end of the year.
Consumer Lifestyle
Consumer Lifestyle comparable sales increased by 6%. The EBITA margin, excluding restructuring charges and other items, improved 260 basis points to 16.0%. The margin increase was largely attributable to higher volumes and improved gross margins.
In Consumer Lifestyle, we were pleased to see that our focused approach continued to deliver strong results, resulting in an improved product mix and strong sales, in particular in Health & Wellness. Our Mother & Child Care line continued to deliver strong double-digit growth, through innovations supporting the healthy development of children. Notably, the new Philips Avent Classic+ bottle is clinically proven to reduce colic and over-eating by allowing newborns to control the milk flow. Our Beauty, Male Grooming, and Oral Healthcare products were successful through the holiday and gift-giving season, including the Double 11 shopping event in China.
Lighting
Lighting (excluding the combined businesses of Lumileds and Automotive) comparable sales declined 3% year-on-year. LED-based sales grew 20%, offset by a decline of 14% in overall conventional lighting sales. LED sales now represent 37% of total Lighting sales, compared to 31% in Q4 2013. The EBITA margin, excluding restructuring and acquisition-related charges and other items, amounted to 9.0%, compared to 8.8% in the fourth quarter of 2013.
As one of the leaders in providing lighting solutions for businesses, cities and consumers that deliver value beyond illumination, we signed a contract to provide the city of Madrid with what is the worlds largest street lighting upgrade to date, involving the replacement of 225,000 luminaires. Our performance in North America was unsatisfactory and our business in China was affected by deteriorating market conditions. We have taken
further steps, including the appointment of a new head of our Americas Lighting business, to significantly strengthen our ability to deliver new levels of business value. Weve also launched exciting new offerings, such as the SlimSurface LED downlight, the thinnest luminaire on the market, which will prove very effective for commercial real-estate customers.
Innovation, Group & Services
EBITA was a net cost of EUR 339 million, including a EUR 201 million provision for ongoing legal matters. Sales decreased from EUR 224 million in Q4 2013 to EUR 184 million in Q4 2014, mainly due to higher one-time settlements in IP royalties in Q4 2013.
We were pleased to receive the CE mark for diagnostic use of our Philips Digital Pathology system and software in the fourth quarter. Pathologists will now be able to use the full digital solution as an aid in diagnosis for routine pathology, which will improve workflows and collaboration and, in turn, increase efficiency and productivity. In the quarter, it is exciting to see that sales in the Healthcare Incubator almost tripled. We also opened a new healthcare imaging systems refurbishment facility in the Netherlands, which marks the next step in bringing the financial and environmental benefits of circular economy to the healthcare industry.
Conference call and audio webcast
Frans van Houten, CEO, and Ron Wirahadiraksa, CFO, will host a conference call for investors and analysts at 10:00 am CET on January 27 to discuss the results. A live audio webcast of the conference call will be available on the Philips Investor Relations website.
Additional Information
This communication is neither an offer to purchase nor a solicitation of an offer to sell any shares of common stock of Volcano or any other securities. Philips has filed a tender offer statement on Schedule TO with the SEC and a Solicitation/Recommendation Statement on Schedule 14D-9 has been filed with the SEC by Volcano. The offer to purchase shares of Volcano common stock will only be made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT, AS FILED AND AS IT MAY BE AMENDED FROM TIME TO TIME, AND THE SOLICITATION/ RECOMMENDATION STATEMENT, AS FILED AND AS MAY BE AMENDED FROM TIME TO TIME, BECAUSE THEY CONTAIN IMPORTANT INFORMATION REGARDING THE OFFER. Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to Georgeson Inc., the Information Agent for the offer, at (866) 856-2826.
Philips Group
Q4 2014 Quarterly report | 5 |
6 | Q4 2014 Quarterly report |
Q4 2014 Quarterly report | 7 |
8 | Q4 2014 Quarterly report |
Q4 2014 Quarterly report | 9 |
10 | Q4 2014 Quarterly report |
Healthcare
Q4 2014 Quarterly report | 11 |
12 | Q4 2014 Quarterly report |
Consumer Lifestyle
Q4 2014 Quarterly report | 13 |
14 | Q4 2014 Quarterly report |
Lighting*
Q4 2014 Quarterly report | 15 |
16 | Q4 2014 Quarterly report |
Additional information on the combined businesses of Lumileds and Automotive
Q4 2014 Quarterly report | 17 |
Innovation, Group & Services
18 | Q4 2014 Quarterly report |
Q4 2014 Quarterly report | 19 |
20 | Q4 2014 Quarterly report |
Full-year highlights
Q4 2014 Quarterly report | 21 |
22 | Q4 2014 Quarterly report |
Q4 2014 Quarterly report | 23 |
24 | Q4 2014 Quarterly report |
Forward-looking statements
Q4 2014 Quarterly report | 25 |
26 | Q4 2014 Quarterly report |
Condensed consolidated statements of income
in millions of euros unless otherwise stated
4th quarter | January to December | |||||||||||||||
2013 | 2014 | 2013 | 2014 | |||||||||||||
Sales |
6,401 | 6,536 | 21,990 | 21,391 | ||||||||||||
Cost of sales |
(3,654 | ) | (4,007 | ) | (12,653 | ) | (13,185 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Gross margin |
2,747 | 2,529 | 9,337 | 8,206 | ||||||||||||
Selling expenses |
(1,425 | ) | (1,499 | ) | (5,057 | ) | (5,124 | ) | ||||||||
General and administrative expenses |
(224 | ) | (213 | ) | (825 | ) | (747 | ) | ||||||||
Research and development expenses |
(449 | ) | (467 | ) | (1,659 | ) | (1,635 | ) | ||||||||
Impairment of goodwill |
(28 | ) | (28 | ) | (3 | ) | ||||||||||
Other business income |
21 | 23 | 122 | 63 | ||||||||||||
Other business expenses |
(15 | ) | (211 | ) | (35 | ) | (274 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Income from operations |
627 | 162 | 1,855 | 486 | ||||||||||||
Financial income |
19 | 19 | 70 | 114 | ||||||||||||
Financial expenses |
(96 | ) | (97 | ) | (400 | ) | (415 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Income before taxes |
550 | 84 | 1,525 | 185 | ||||||||||||
Income tax expense |
(161 | ) | (16 | ) | (466 | ) | (26 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Income after taxes |
389 | 68 | 1,059 | 159 | ||||||||||||
Results relating to investments in associates |
(46 | ) | (1 | ) | (25 | ) | 62 | |||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income from continuing operations |
343 | 67 | 1,034 | 221 | ||||||||||||
Discontinued operations - net of income tax |
69 | 67 | 138 | 190 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net income |
412 | 134 | 1,172 | 411 | ||||||||||||
Attribution of net income for the period |
||||||||||||||||
Net income attributable to shareholders |
409 | 139 | 1,169 | 415 | ||||||||||||
Net income (loss) attributable to non-controlling interests |
3 | (5 | ) | 3 | (4 | ) | ||||||||||
Earnings per common share attributable to shareholders |
||||||||||||||||
Weighted average number of common shares outstanding (after deduction of treasury shares) during the period (in thousands): |
||||||||||||||||
- basic |
914,385 | 916,767 | 911,072 | 915,193 | ||||||||||||
- diluted |
927,131 | 922,270 | 922,072 | 922,714 | ||||||||||||
Net income attributable to shareholders per common share in euros: |
||||||||||||||||
- basic |
0.45 | 0.15 | 1.28 | 0.45 | ||||||||||||
- diluted |
0.44 | 0.15 | 1.27 | 0.45 |
Q4 2014 Quarterly report | 27 |
Condensed consolidated balance sheets
in millions of euros unless otherwise stated
December 31, 2013 |
December 31, 2014 |
|||||||
Non-current assets: |
||||||||
Property, plant and equipment |
2,780 | 2,095 | ||||||
Goodwill |
6,504 | 7,158 | ||||||
Intangible assets excluding goodwill |
3,262 | 3,368 | ||||||
Non-current receivables |
144 | 177 | ||||||
Investments in associates |
161 | 157 | ||||||
Other non-current financial assets |
496 | 462 | ||||||
Deferred tax assets |
1,675 | 2,460 | ||||||
Other non-current assets |
63 | 69 | ||||||
|
|
|
|
|||||
Total non-current assets |
15,085 | 15,946 | ||||||
Current assets: |
||||||||
Inventories |
3,240 | 3,314 | ||||||
Other current financial assets |
10 | 125 | ||||||
Other current assets |
354 | 411 | ||||||
Derivative financial assets |
150 | 207 | ||||||
Income tax receivable |
70 | 140 | ||||||
Receivables |
4,678 | 4,723 | ||||||
Assets classified as held for sale |
507 | 1,613 | ||||||
Cash and cash equivalents |
2,465 | 1,873 | ||||||
|
|
|
|
|||||
Total current assets |
11,474 | 12,406 | ||||||
|
|
|
|
|||||
Total assets |
26,559 | 28,352 | ||||||
Shareholders equity |
11,214 | 10,867 | ||||||
Non-controlling interests |
13 | 101 | ||||||
|
|
|
|
|||||
Group equity |
11,227 | 10,968 | ||||||
Non-current liabilities: |
||||||||
Long-term debt |
3,309 | 3,712 | ||||||
Long-term provisions |
1,903 | 2,500 | ||||||
Deferred tax liabilities |
76 | 107 | ||||||
Other non-current liabilities |
1,568 | 1,838 | ||||||
|
|
|
|
|||||
Total non-current liabilities |
6,856 | 8,157 | ||||||
Current liabilities: |
||||||||
Short-term debt |
592 | 392 | ||||||
Derivative financial liabilities |
368 | 857 | ||||||
Income tax payable |
143 | 102 | ||||||
Accounts and notes payable |
2,462 | 2,499 | ||||||
Accrued liabilities |
2,830 | 2,692 | ||||||
Short-term provisions |
651 | 945 | ||||||
Liabilities directly associated with assets held for sale |
348 | 349 | ||||||
Other current liabilities |
1,082 | 1,391 | ||||||
|
|
|
|
|||||
Total current liabilities |
8,476 | 9,227 | ||||||
|
|
|
|
|||||
Total liabilities and group equity |
26,559 | 28,352 |
28 | Q4 2014 Quarterly report |
Condensed consolidated statements of cash flows
in millions of euros
4th quarter | January to December | |||||||||||||||
2013 | 2014 | 2013 | 2014 | |||||||||||||
Cash flows from operating activities: |
||||||||||||||||
Net income |
412 | 134 | 1,172 | 411 | ||||||||||||
Result of discontinued operations - net of income tax |
(69 | ) | (67 | ) | (138 | ) | (190 | ) | ||||||||
Adjustments to reconcile net income to net cash provided by (used for) operating activities: |
||||||||||||||||
Depreciation, amortization, and impairments of fixed assets |
366 | 393 | 1,177 | 1,187 | ||||||||||||
Impairment of goodwill and other non-current financial assets |
32 | 3 | 38 | 21 | ||||||||||||
Net gain on sale of assets |
(5 | ) | (9 | ) | (54 | ) | (83 | ) | ||||||||
Interest income |
(14 | ) | (11 | ) | (54 | ) | (39 | ) | ||||||||
Interest expense on debt, borrowings and other liabilities |
61 | 63 | 258 | 231 | ||||||||||||
Income tax expense |
161 | 16 | 466 | 26 | ||||||||||||
Results from investments in associates |
47 | 2 | 25 | (62 | ) | |||||||||||
(Increase) decrease in working capital: |
(295 | ) | 349 | (1,272 | ) | 590 | ||||||||||
(Increase) decrease in receivables and other current assets |
(190 | ) | 27 | (500 | ) | (48 | ) | |||||||||
(Increase) decrease in inventories |
466 | 399 | (165 | ) | (77 | ) | ||||||||||
(Decrease) increase in accounts payable, accrued and other liabilities |
(571 | ) | (77 | ) | (607 | ) | 715 | |||||||||
Increase in non-current receivables, other assets and other liabilities |
(36 | ) | (114 | ) | (159 | ) | (690 | ) | ||||||||
Increase (decrease) in provisions |
53 | 230 | (194 | ) | 640 | |||||||||||
Other items |
130 | (85 | ) | 299 | (242 | ) | ||||||||||
Interest paid |
(30 | ) | (26 | ) | (267 | ) | (232 | ) | ||||||||
Interest received |
14 | 11 | 52 | 38 | ||||||||||||
Dividends received from investments in associates |
| 8 | 6 | 41 | ||||||||||||
Dividends paid to non-controlling interests |
(7 | ) | | (7 | ) | | ||||||||||
Income taxes paid |
(74 | ) | (56 | ) | (436 | ) | (344 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash provided by operating activities |
746 | 841 | 912 | 1,303 | ||||||||||||
Cash flows from investing activities: |
||||||||||||||||
Net capital expenditures |
(265 | ) | (282 | ) | (830 | ) | (806 | ) | ||||||||
Purchase of intangible assets |
(32 | ) | (56 | ) | (49 | ) | (114 | ) | ||||||||
Expenditures on development assets |
(81 | ) | (88 | ) | (326 | ) | (295 | ) | ||||||||
Capital expenditures on property, plant and equipment |
(156 | ) | (153 | ) | (482 | ) | (437 | ) | ||||||||
Proceeds from sale of property, plant and equipment |
4 | 15 | 27 | 40 | ||||||||||||
Cash used for derivatives and current financial assets |
(7 | ) | (12 | ) | (101 | ) | (7 | ) | ||||||||
Purchase of other non-current financial assets |
(8 | ) | (7 | ) | (13 | ) | (81 | ) | ||||||||
Proceeds from other non-current financial assets |
(1 | ) | 14 | 14 | 107 | |||||||||||
Purchase of businesses, net of cash acquired |
(6 | ) | (13 | ) | (11 | ) | (177 | ) | ||||||||
Net proceeds from (used for) sale of interest in businesses |
(6 | ) | 39 | 79 | (20 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash used for investing activities |
(293 | ) | (261 | ) | (862 | ) | (984 | ) | ||||||||
Cash flows from financing activities: |
||||||||||||||||
Proceeds from issuance (payments) of short-term debt |
(82 | ) | (371 | ) | (285 | ) | (37 | ) | ||||||||
Principal payments on long-term debt |
(19 | ) | (19 | ) | (186 | ) | (333 | ) | ||||||||
Proceeds from issuance of long-term debt |
16 | 24 | 64 | 69 | ||||||||||||
Treasury shares transactions |
(57 | ) | (134 | ) | (562 | ) | (596 | ) | ||||||||
Dividend paid |
| | (272 | ) | (292 | ) | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash used for financing activities |
(142 | ) | (500 | ) | (1,241 | ) | (1,189 | ) |
Q4 2014 Quarterly report | 29 |
4th quarter | January to December | |||||||||||||||
2013 | 2014 | 2013 | 2014 | |||||||||||||
Net cash (used for) provided by continuing operations |
311 | 80 | (1,191 | ) | (870 | ) | ||||||||||
Cash flows from discontinued operations: |
||||||||||||||||
Net cash (used for) provided by operating activities |
145 | 49 | (68 | ) | 105 | |||||||||||
Net cash (used for) provided by investing activities |
3 | (11 | ) | (47 | ) | 88 | ||||||||||
|
|
|
|
|
|
|
|
|||||||||
Net cash (used for) provided by discontinued operations |
148 | 38 | (115 | ) | 193 | |||||||||||
Net cash (used for) provided by continuing and discontinued operations |
459 | 118 | (1,306 | ) | (677 | ) | ||||||||||
Effect of change in exchange rates on cash and cash equivalents |
(28 | ) | 39 | (63 | ) | 85 | ||||||||||
Cash and cash equivalents at the beginning of the period |
2,034 | 1,716 | 3,834 | 2,465 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash and cash equivalents at the end of the period |
2,465 | 1,873 | 2,465 | 1,873 |
For a number of reasons, principally the effects of translation differences, certain items in the statements of cash flows do not correspond to the differences between the balance sheet amounts for the respective items.
30 | Q4 2014 Quarterly report |
Condensed consolidated statement of changes in equity
in millions of euros
common shares |
capital in excess of par value |
retained earnings |
revaluation reserve |
currency translation differences |
available- for-sale financial |
cash flow hedges |
treasury shares at cost |
total shareholders equity |
non- controlling interests |
total equity |
||||||||||||||||||||||||||||||||||
January-December 2014 |
||||||||||||||||||||||||||||||||||||||||||||
Balance as of December 31, 2013 |
188 | 1,796 | 10,415 | 23 | (569 | ) | 55 | 24 | (718 | ) | 11,214 | 13 | 11,227 | |||||||||||||||||||||||||||||||
Total comprehensive income |
(258 | ) | (10 | ) | 798 | (28 | ) | (37 | ) | 465 | (4 | ) | 461 | |||||||||||||||||||||||||||||||
Dividend distributed |
3 | 433 | (729 | ) | (293 | ) | (293 | ) | ||||||||||||||||||||||||||||||||||||
Movement non-controlling interest |
| 92 | 92 | |||||||||||||||||||||||||||||||||||||||||
Purchase of treasury shares |
(26 | ) | (688 | ) | (714 | ) | (714 | ) | ||||||||||||||||||||||||||||||||||||
Re-issuance of treasury shares |
(127 | ) | (83 | ) | 326 | 116 | 116 | |||||||||||||||||||||||||||||||||||||
Cancellation of treasury shares |
(4 | ) | (529 | ) | 533 | | | |||||||||||||||||||||||||||||||||||||
Share-based compensation plans |
88 | 88 | 88 | |||||||||||||||||||||||||||||||||||||||||
Income tax share-based compensation plans |
(9 | ) | (9 | ) | (9 | ) | ||||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Total other equity movements |
(1 | ) | 385 | (1,367 | ) | 171 | (812 | ) | 92 | (720 | ) | |||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||
Balance as of December 31, 2014 |
187 | 2,181 | 8,790 | 13 | 229 | 27 | (13 | ) | (547 | ) | 10,867 | 101 | 10,968 |
Q4 2014 Quarterly report | 31 |
Pension costs and cash flows
in millions of euros
Specification of pension costs
4th quarter | ||||||||||||||||||||||||
2013 | 2014 | |||||||||||||||||||||||
Netherlands | other | total | Netherlands | other | total | |||||||||||||||||||
Defined-benefit plans |
||||||||||||||||||||||||
Pensions |
||||||||||||||||||||||||
Current service cost |
48 | 18 | 66 | 44 | 17 | 61 | ||||||||||||||||||
Past service cost (incl. curtailments) |
| (3 | ) | (3 | ) | (68 | ) | (1 | ) | (69 | ) | |||||||||||||
Settlements |
| 1 | 1 | | (1 | ) | (1 | ) | ||||||||||||||||
Interest expense |
| 16 | 16 | | 17 | 17 | ||||||||||||||||||
Interest income |
(1 | ) | 0 | (1 | ) | (3 | ) | | (3 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
47 | 32 | 79 | (27 | ) | 32 | 5 | |||||||||||||||||
of which discontinued operations |
1 | | 1 | | 1 | 1 | ||||||||||||||||||
Retiree Medical |
||||||||||||||||||||||||
Current service cost |
| | | | 1 | 1 | ||||||||||||||||||
Interest expense |
| 2 | 2 | | 2 | 2 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
| 2 | 2 | | 3 | 3 | ||||||||||||||||||
Defined-contribution plans |
||||||||||||||||||||||||
Cost |
1 | 29 | 30 | 10 | 31 | 41 | ||||||||||||||||||
of which discontinued operations |
| 2 | 2 | | 1 | 1 | ||||||||||||||||||
Specification of pension costs
|
|
|||||||||||||||||||||||
January to December | ||||||||||||||||||||||||
2013 | 2014 | |||||||||||||||||||||||
Netherlands | other | total | Netherlands | other | total | |||||||||||||||||||
Defined-benefit plans |
||||||||||||||||||||||||
Pensions |
||||||||||||||||||||||||
Current service cost |
192 | 82 | 274 | 183 | 71 | 254 | ||||||||||||||||||
Past service cost (incl. curtailments) |
| (81 | ) | (81 | ) | (68 | ) | (1 | ) | (69 | ) | |||||||||||||
Settlements |
| 32 | 32 | 0 | (1 | ) | (1 | ) | ||||||||||||||||
Interest expense |
| 65 | 65 | 0 | 59 | 59 | ||||||||||||||||||
Interest income |
(4 | ) | | (4 | ) | (11 | ) | 0 | (11 | ) | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
188 | 98 | 286 | 104 | 128 | 232 | ||||||||||||||||||
of which discontinued operations |
4 | 2 | 6 | 1 | 3 | 4 | ||||||||||||||||||
Retiree Medical |
||||||||||||||||||||||||
Current service cost |
| 1 | 1 | | 2 | 2 | ||||||||||||||||||
Interest expense |
| 10 | 10 | | 11 | 11 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Total |
| 11 | 11 | | 13 | 13 | ||||||||||||||||||
Defined-contribution plans |
||||||||||||||||||||||||
Costs |
8 | 134 | 142 | 16 | 132 | 148 | ||||||||||||||||||
of which discontinued operations |
| 8 | 8 | 1 | 3 | 4 |
Pension cash flows
4th quarter | January to December | |||||||||||||||
2013 | 2014 | 2013 | 2014 | |||||||||||||
Contributions and benefits paid by the Company |
190 | 205 | 679 | 1,050 |
32 | Q4 2014 Quarterly report |
Sectors
in millions of euros unless otherwise stated
Sales and income from operations
4th quarter | ||||||||||||||||||||||||
2013 | 2014 | |||||||||||||||||||||||
sales | income from operations | sales | income from operations | |||||||||||||||||||||
|
|
|
|
|||||||||||||||||||||
as a % of sales |
as a % of sales |
|||||||||||||||||||||||
Healthcare |
2,828 | 477 | 16.9 | 2,849 | 351 | 12.3 | ||||||||||||||||||
Consumer Lifestyle |
1,428 | 174 | 12.2 | 1,528 | 237 | 15.5 | ||||||||||||||||||
Lighting |
1,921 | 55 | 2.9 | 1,975 | (83 | ) | (4.2 | ) | ||||||||||||||||
Innovation, Group & Services |
224 | (79 | ) | | 184 | (343 | ) | | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Philips Group |
6,401 | 627 | 9.8 | 6,536 | 162 | 2.5 |
Sales and income from operations
January to December | ||||||||||||||||||||||||
2013 | 2014 | |||||||||||||||||||||||
sales | income from operations | sales | income from operations | |||||||||||||||||||||
|
|
|
|
|||||||||||||||||||||
as a % of sales |
as a % of sales |
|||||||||||||||||||||||
Healthcare |
9,575 | 1,315 | 13.7 | 9,186 | 456 | 5.0 | ||||||||||||||||||
Consumer Lifestyle |
4,605 | 429 | 9.3 | 4,731 | 520 | 11.0 | ||||||||||||||||||
Lighting |
7,145 | 413 | 5.8 | 6,869 | 185 | 2.7 | ||||||||||||||||||
Innovation, Group & Services |
665 | (302 | ) | | 605 | (675 | ) | | ||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Philips Group |
21,990 | 1,855 | 8.4 | 21,391 | 486 | 2.3 |
Q4 2014 Quarterly report | 33 |
Sectors and main countries
in millions of euros
Sales, total assets and total liabilities excluding debt
sales | total assets | total liabilities excluding debt | ||||||||||||||||||||||
January to December | December 31, | December 31, | December 31, | December 31, | ||||||||||||||||||||
2013 | 2014 | 2013 | 2014 | 2013 | 2014 | |||||||||||||||||||
Healthcare |
9,575 | 9,186 | 10,465 | 11,274 | 2,943 | 3,629 | ||||||||||||||||||
Consumer Lifestyle |
4,605 | 4,731 | 2,832 | 3,049 | 1,571 | 1,696 | ||||||||||||||||||
Lighting |
7,145 | 6,869 | 6,711 | 5,739 | 2,229 | 2,081 | ||||||||||||||||||
Innovation, Group & Services |
665 | 605 | 6,044 | 6,677 | 4,340 | 5,525 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|||||||||||||||||
26,052 | 26,739 | 11,083 | 12,931 | |||||||||||||||||||||
Assets and liabilities classified as held for sale |
507 | 1,613 | 348 | 349 | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||
Philips Group |
21,990 | 21,391 | 26,559 | 28,352 | 11,431 | 13,280 |
Sales and tangible and intangible assets
sales | tangible and intangible assets1) | |||||||||||||||
January to December | December 31, | December 31, | ||||||||||||||
2013 | 2014 | 2013 | 2014 | |||||||||||||
Netherlands |
649 | 594 | 915 | 937 | ||||||||||||
United States |
6,325 | 6,160 | 7,384 | 7,649 | ||||||||||||
China |
2,616 | 2,362 | 1,057 | 1,135 | ||||||||||||
Germany |
1,316 | 1,351 | 288 | 153 | ||||||||||||
Japan |
943 | 908 | 401 | 379 | ||||||||||||
France |
890 | 839 | 80 | 52 | ||||||||||||
United Kingdom |
677 | 722 | 573 | 594 | ||||||||||||
Other countries |
8,574 | 8,455 | 1,848 | 1,722 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Philips Group |
21,990 | 21,391 | 12,546 | 12,621 |
1) | Includes property, plant and equipment, goodwill, and intangible assets excluding goodwill |
34 | Q4 2014 Quarterly report |
Reconciliation of non-GAAP performance measures
in millions of euros unless otherwise stated
Certain non-GAAP financial measures are presented when discussing the Philips Groups performance. In the following tables, reconciliations to the most directly comparable IFRS measures are presented.
Sales growth composition (in %)
4th quarter | January to December | |||||||||||||||||||||||||||||||
comparable growth |
currency effects |
consolidation changes |
nominal growth |
comparable growth |
currency effects |
consolidation changes |
nominal growth |
|||||||||||||||||||||||||
2014 versus 2013 |
||||||||||||||||||||||||||||||||
Healthcare |
(2.9 | ) | 3.8 | (0.2 | ) | 0.7 | (2.0 | ) | (1.6 | ) | (0.5 | ) | (4.1 | ) | ||||||||||||||||||
Consumer Lifestyle |
5.6 | 1.4 | 0.0 | 7.0 | 5.8 | (3.1 | ) | 0.0 | 2.7 | |||||||||||||||||||||||
Lighting |
(2.7 | ) | 2.9 | 2.6 | 2.8 | (2.6 | ) | (2.3 | ) | 1.0 | (3.9 | ) | ||||||||||||||||||||
IG&S |
(21.0 | ) | 0.8 | 2.3 | (17.9 | ) | (11.8 | ) | (0.1 | ) | 2.9 | (9.0 | ) | |||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||
Philips Group |
(1.6 | ) | 3.0 | 0.7 | 2.1 | (0.9 | ) | (2.0 | ) | 0.2 | (2.7 | ) |
EBITA excluding restructuring and acquisition-related charges and other items to Income from operations (or EBIT)
4th quarter | January to December | |||||||||||||||||||||||||||||||||||||||
Philips Group |
Healthcare | Consumer Lifestyle |
Lighting | Innovation, Group & Services |
Philips Group |
Healthcare | Consumer Lifestyle |
Lighting | Innovation, Group & Services |
|||||||||||||||||||||||||||||||
2014 |
||||||||||||||||||||||||||||||||||||||||
EBITA excluding restructuring and acquisition-related charges and other items |
743 | 421 | 244 | 178 | (100 | ) | 1,915 | 1,085 | 571 | 593 | (334 | ) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Other items |
(202 | ) | 16 | 11 | (55 | ) | (174 | ) | (660 | ) | (399 | ) | 11 | (55 | ) | (217 | ) | |||||||||||||||||||||||
Restructuring and acquisition-related charges |
(279 | ) | (47 | ) | (4 | ) | (163 | ) | (65 | ) | (434 | ) | (70 | ) | (9 | ) | (245 | ) | (110 | ) | ||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
EBITA (or Adjusted income from operations) |
262 | 390 | 251 | (40 | ) | (339 | ) | 821 | 616 | 573 | 293 | (661 | ) | |||||||||||||||||||||||||||
Amortization of intangibles1) |
(100 | ) | (39 | ) | (14 | ) | (43 | ) | (4 | ) | (332 | ) | (159 | ) | (53 | ) | (106 | ) | (14 | ) | ||||||||||||||||||||
Impairment of goodwill |
(3 | ) | (1 | ) | (2 | ) | ||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Income from operations (or EBIT) |
162 | 351 | 237 | (83 | ) | (343 | ) | 486 | 456 | 520 | 185 | (675 | ) | |||||||||||||||||||||||||||
2013 |
||||||||||||||||||||||||||||||||||||||||
EBITA excluding restructuring and acquisition-related charges and other items |
827 | 538 | 192 | 169 | (72 | ) | 2,308 | 1,430 | 496 | 653 | (271 | ) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Other items |
68 | 82 | 1 | 10 | (25 | ) | ||||||||||||||||||||||||||||||||||
Restructuring and acquisition-related charges |
(38 | ) | 3 | (5 | ) | (29 | ) | (7 | ) | (100 | ) | (14 | ) | (83 | ) | (3 | ) | |||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
EBITA (or adjusted income from operations) |
789 | 541 | 187 | 140 | (79 | ) | 2,276 | 1,512 | 483 | 580 | (299 | ) | ||||||||||||||||||||||||||||
Amortization of intangibles1) |
(134 | ) | (62 | ) | (13 | ) | (59 | ) | (393 | ) | (195 | ) | (54 | ) | (141 | ) | (3 | ) | ||||||||||||||||||||||
Impairment of goodwill |
(28 | ) | (2 | ) | (26 | ) | (28 | ) | (2 | ) | (26 | ) | ||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||
Income from operations (or EBIT) |
627 | 477 | 174 | 55 | (79 | ) | 1,855 | 1,315 | 429 | 413 | (302 | ) |
1) | Excluding amortization of software and product development |
Q4 2014 Quarterly report | 35 |
Reconciliation of non-GAAP performance measures (continued)
all amounts in millions of euros
Net operating capital to total assets
Philips Group | Healthcare | Consumer Lifestyle |
Lighting | IG&S | ||||||||||||||||
December 31, 2014 |
||||||||||||||||||||
Net operating capital (NOC) |
8,838 | 7,565 | 1,353 | 3,638 | (3,718 | ) | ||||||||||||||
Exclude liabilities comprised in NOC: |
||||||||||||||||||||
- payables/liabilities |
9,379 | 2,711 | 1,411 | 1,422 | 3,835 | |||||||||||||||
- intercompany accounts |
| 125 | 65 | 129 | (319 | ) | ||||||||||||||
- provisions |
3,445 | 793 | 220 | 530 | 1,902 | |||||||||||||||
Include assets not comprised in NOC: |
||||||||||||||||||||
- investments in associates |
157 | 80 | | 20 | 57 | |||||||||||||||
- other current financial assets |
125 | 125 | ||||||||||||||||||
- other non-current financial assets |
462 | 462 | ||||||||||||||||||
- deferred tax assets |
2,460 | 2,460 | ||||||||||||||||||
- cash and cash equivalents |
1,873 | 1,873 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
26,739 | 11,274 | 3,049 | 5,739 | 6,677 | ||||||||||||||||
Assets classified as held for sale |
1,613 | |||||||||||||||||||
|
|
|||||||||||||||||||
Total assets |
28,352 | |||||||||||||||||||
December 31, 2013 |
||||||||||||||||||||
Net operating capital (NOC) |
10,238 | 7,437 | 1,261 | 4,462 | (2,922 | ) | ||||||||||||||
Exclude liabilities comprised in NOC: |
||||||||||||||||||||
- payables/liabilities |
8,453 | 2,541 | 1,275 | 1,672 | 2,965 | |||||||||||||||
- intercompany accounts |
| 124 | 75 | 105 | (304 | ) | ||||||||||||||
- provisions |
2,554 | 278 | 221 | 452 | 1,603 | |||||||||||||||
Include assets not comprised in NOC: |
||||||||||||||||||||
- investments in associates |
161 | 85 | | 20 | 56 | |||||||||||||||
- other current financial assets |
10 | 10 | ||||||||||||||||||
- other non-current financial assets |
496 | 496 | ||||||||||||||||||
- deferred tax assets |
1,675 | 1,675 | ||||||||||||||||||
- cash and cash equivalents |
2,465 | 2,465 | ||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|||||||||||
26,052 | 10,465 | 2,832 | 6,711 | 6,044 | ||||||||||||||||
Assets classified as held for sale |
507 | |||||||||||||||||||
|
|
|||||||||||||||||||
Total assets |
26,559 |
36 | Q4 2014 Quarterly report |
Reconciliation of non-GAAP performance measures (continued)
all amounts in millions of euros unless otherwise stated
Composition of net debt to group equity
December 31, 2013 |
December 31, 2014 |
|||||||
Long-term debt |
3,309 | 3,712 | ||||||
Short-term debt |
592 | 392 | ||||||
|
|
|
|
|||||
Total debt |
3,901 | 4,104 | ||||||
Cash and cash equivalents |
2,465 | 1,873 | ||||||
|
|
|
|
|||||
Net debt (cash) (total debt less cash and cash equivalents) |
1,436 | 2,231 | ||||||
Shareholders equity |
11,214 | 10,867 | ||||||
Non-controlling interests |
13 | 101 | ||||||
|
|
|
|
|||||
Group equity |
11,227 | 10,968 | ||||||
Net debt and group equity |
12,663 | 13,199 | ||||||
Net debt divided by net debt and group equity (in %) |
11 | 17 | ||||||
Group equity divided by net debt and group equity (in %) |
89 | 83 |
Composition of cash flows
4th quarter | January to December | |||||||||||||||
2013 | 2014 | 2013 | 2014 | |||||||||||||
Cash flows provided by operating activities |
746 | 841 | 912 | 1,303 | ||||||||||||
Cash flows used for investing activities |
(293 | ) | (261 | ) | (862 | ) | (984 | ) | ||||||||
|
|
|
|
|
|
|
|
|||||||||
Cash flows before financing activities |
453 | 580 | 50 | 319 | ||||||||||||
Cash flows provided by operating activities |
746 | 841 | 912 | 1,303 | ||||||||||||
Net capital expenditures: |
(265 | ) | (282 | ) | (830 | ) | (806 | ) | ||||||||
Purchase of intangible assets |
(32 | ) | (56 | ) | (49 | ) | (114 | ) | ||||||||
Expenditures on development assets |
(81 | ) | (88 | ) | (326 | ) | (295 | ) | ||||||||
Capital expenditures on property, plant and equipment |
(156 | ) | (153 | ) | (482 | ) | (437 | ) | ||||||||
Proceeds from sale of property, plant and equipment |
4 | 15 | 27 | 40 | ||||||||||||
|
|
|
|
|
|
|
|
|||||||||
Free cash flows |
481 | 559 | 82 | 497 |
Q4 2014 Quarterly report | 37 |
Philips statistics
all amounts in millions of euros unless otherwise stated
2013 | 2014 | |||||||||||||||||||||||||||||||
1st quarter | 2nd quarter | 3rd quarter | 4th quarter | 1st quarter | 2nd quarter | 3rd quarter | 4th quarter | |||||||||||||||||||||||||
Sales |
4,973 | 5,348 | 5,268 | 6,401 | 4,692 | 4,969 | 5,194 | 6,536 | ||||||||||||||||||||||||
comparable sales growth % |
1 | 2 | 2 | 6 | (1 | ) | (1 | ) | (2 | ) | (2 | ) | ||||||||||||||||||||
Gross margin |
2,040 | 2,287 | 2,263 | 2,747 | 1,900 | 2,075 | 1,702 | 2,529 | ||||||||||||||||||||||||
as a % of sales |
41.0 | 42.8 | 43.0 | 42.9 | 40.5 | 41.8 | 32.8 | 38.7 | ||||||||||||||||||||||||
Selling expenses |
(1,183 | ) | (1,237 | ) | (1,212 | ) | (1,425 | ) | (1,166 | ) | (1,214 | ) | (1,245 | ) | (1,499 | ) | ||||||||||||||||
as a % of sales |
(23.8 | ) | (23.1 | ) | (23.0 | ) | (22.3 | ) | (24.9 | ) | (24.4 | ) | (24.0 | ) | (22.9 | ) | ||||||||||||||||
G&A expenses |
(182 | ) | (203 | ) | (216 | ) | (224 | ) | (167 | ) | (176 | ) | (191 | ) | (213 | ) | ||||||||||||||||
as a % of sales |
(3.7 | ) | (3.8 | ) | (4.1 | ) | (3.5 | ) | (3.6 | ) | (3.5 | ) | (3.7 | ) | (3.3 | ) | ||||||||||||||||
R&D expenses |
(406 | ) | (399 | ) | (405 | ) | (449 | ) | (396 | ) | (400 | ) | (372 | ) | (467 | ) | ||||||||||||||||
as a % of sales |
(8.2 | ) | (7.5 | ) | (7.7 | ) | (7.0 | ) | (8.4 | ) | (8.0 | ) | (7.2 | ) | (7.1 | ) | ||||||||||||||||
EBIT |
286 | 500 | 442 | 627 | 172 | 291 | (139 | ) | 162 | |||||||||||||||||||||||
as a % of sales |
5.8 | 9.3 | 8.4 | 9.8 | 3.7 | 5.9 | (2.7 | ) | 2.5 | |||||||||||||||||||||||
EBITA |
373 | 584 | 530 | 789 | 253 | 368 | (62 | ) | 262 | |||||||||||||||||||||||
as a % of sales |
7.5 | 10.9 | 10.1 | 12.3 | 5.4 | 7.4 | (1.2 | ) | 4.0 | |||||||||||||||||||||||
Net income (loss) |
162 | 317 | 281 | 412 | 137 | 243 | (103 | ) | 134 | |||||||||||||||||||||||
Net income (loss) attributable to shareholders |
161 | 317 | 282 | 409 | 138 | 242 | (104 | ) | 139 | |||||||||||||||||||||||
Net income (loss) - shareholders per common share in euros - diluted |
0.17 | 0.35 | 0.31 | 0.44 | 0.15 | 0.26 | (0.11 | ) | 0.15 |
38 | Q4 2014 Quarterly report |
Philips statistics (continued)
all amounts in millions of euros unless otherwise stated
2013 | 2014 | |||||||||||||||||||||||||||||||
January- March |
January- June |
January- September |
January- December |
January- March |
January- June |
January- September |
January- December |
|||||||||||||||||||||||||
Sales |
4,973 | 10,321 | 15,589 | 21,990 | 4,692 | 9,661 | 14,855 | 21,391 | ||||||||||||||||||||||||
comparable sales growth % |
1 | 1 | 2 | 3 | (1 | ) | (1 | ) | 0 | (1 | ) | |||||||||||||||||||||
Gross margin |
2,040 | 4,327 | 6,590 | 9,337 | 1,900 | 3,975 | 5,677 | 8,206 | ||||||||||||||||||||||||
as a % of sales |
41.0 | 41.9 | 42.3 | 42.5 | 40.5 | 41.1 | 38.2 | 38.4 | ||||||||||||||||||||||||
Selling expenses |
(1,183 | ) | (2,420 | ) | (3,632 | ) | (5,057 | ) | (1,166 | ) | (2,380 | ) | (3,625 | ) | (5,124 | ) | ||||||||||||||||
as a % of sales |
(23.8 | ) | (23.4 | ) | (23.3 | ) | (23.0 | ) | (24.9 | ) | (24.6 | ) | (24.4 | ) | (24.0 | ) | ||||||||||||||||
G&A expenses |
(182 | ) | (385 | ) | (601 | ) | (825 | ) | (167 | ) | (343 | ) | (534 | ) | (747 | ) | ||||||||||||||||
as a % of sales |
(3.7 | ) | (3.7 | ) | (3.9 | ) | (3.8 | ) | (3.6 | ) | (3.6 | ) | (3.6 | ) | (3.5 | ) | ||||||||||||||||
R&D expenses |
(406 | ) | (805 | ) | (1,210 | ) | (1,659 | ) | (396 | ) | (796 | ) | (1,168 | ) | (1,635 | ) | ||||||||||||||||
as a % sales |
(8.2 | ) | (7.8 | ) | (7.8 | ) | (7.5 | ) | (8.4 | ) | (8.2 | ) | (7.9 | ) | (7.6 | ) | ||||||||||||||||
EBIT |
286 | 786 | 1,228 | 1,855 | 172 | 463 | 324 | 486 | ||||||||||||||||||||||||
as a % of sales |
5.8 | 7.6 | 7.9 | 8.4 | 3.7 | 4.8 | 2.2 | 2.3 | ||||||||||||||||||||||||
EBITA |
373 | 957 | 1,487 | 2,276 | 253 | 621 | 559 | 821 | ||||||||||||||||||||||||
as a % of sales |
7.5 | 9.3 | 9.5 | 10.4 | 5.4 | 6.4 | 3.8 | 3.8 | ||||||||||||||||||||||||
Net income |
162 | 479 | 760 | 1,172 | 137 | 380 | 277 | 411 | ||||||||||||||||||||||||
Net income attributable to shareholders |
161 | 478 | 760 | 1,169 | 138 | 380 | 276 | 415 | ||||||||||||||||||||||||
Net income - shareholders per common share in euros - diluted |
0.17 | 0.52 | 0.83 | 1.27 | 0.15 | 0.41 | 0.30 | 0.45 | ||||||||||||||||||||||||
Net income from continuing operations as a % of shareholders equity |
5.4 | 8.5 | 8.7 | 9.4 | 4.0 | 5.7 | 2.0 | 2.0 | ||||||||||||||||||||||||
period ended 2013 | period ended 2014 | |||||||||||||||||||||||||||||||
Number of common shares outstanding (after deduction of treasury shares) at the end of period (in thousands) |
905,381 | 913,874 | 915,095 | 913,338 | 913,485 | 923,933 | 919,973 | 914,389 | ||||||||||||||||||||||||
Shareholders equity per common share in euros |
12.33 | 11.78 | 11.93 | 12.28 | 12.06 | 11.63 | 11.86 | 11.88 | ||||||||||||||||||||||||
Inventories as a % of sales1) |
15.2 | 15.5 | 16.3 | 13.7 | 14.8 | 15.9 | 17.4 | 15.5 | ||||||||||||||||||||||||
Inventories excluding discontinued operations |
3,376 | 3,441 | 3,579 | 3,021 | 3,215 | 3,387 | 3,690 | 3,313 | ||||||||||||||||||||||||
Net debt : group equity ratio |
12:88 | 16:84 | 16:84 | 11:89 | 15:85 | 18:82 | 19:81 | 17:83 | ||||||||||||||||||||||||
Net operating capital |
9,969 | 10,184 | 10,249 | 10,238 | 10,381 | 10,500 | 10,841 | 8,838 | ||||||||||||||||||||||||
Total employees |
118,085 | 117,369 | 115,858 | 116,082 | 114,268 | 112,834 | 115,261 | 113,678 | ||||||||||||||||||||||||
of which discontinued operations |
10,812 | 10,764 | 10,499 | 10,445 | 9,957 | 8,256 | 8,489 | 8,313 |
1) | sales is calculated over the preceding 12 months |
Q4 2014 Quarterly report | 39 |